Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II StudyAndrew B. Lassman, Patrick Roth, Filip De Vos et al.|Zurich Open Repository and Archive (University of Zurich)|2022Cited by 76
P1132: LONG-TERM RESPONSES WITH LONCASTUXIMAB TESIRINE: UPDATED RESULTS FROM LOTIS-2, THE PIVOTAL PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMAPaolo F. Caimi, Carmelo Carlo‐Stella, Weiyun Z. Ai et al.|HemaSphere|2023Cited by 3
Supplementary Figure from Infigratinib in Patients with Recurrent Gliomas and <i>FGFR</i> Alterations: A Multicenter Phase II StudyAndrew B. Lassman, Patrick Roth, Juan Manuel Sepúlveda-Sánchez et al.|Unknown|2023Cited by 0